within Pharmacolibrary.Drugs.ATC.L;

model L01XX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 75 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,
    adminCount     = 1,
    Vd             = 0.0211,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pentostatin is an antineoplastic agent and purine analog that acts as an adenosine deaminase inhibitor. It is used mainly for the treatment of hairy cell leukemia and has also been studied in other hematological malignancies. It is approved for use in several countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with normal renal function and various hematologic malignancies, main route intravenous administration.</p><h4>References</h4><ol><li><p>Lathia, C, et al., &amp; Whitfield, L (2002). Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. <i>Cancer chemotherapy and pharmacology</i> 50(2) 121–126. DOI:<a href=&quot;https://doi.org/10.1007/s00280-002-0468-9&quot;>10.1007/s00280-002-0468-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12172976/&quot;>https://pubmed.ncbi.nlm.nih.gov/12172976</a></p></li><li><p>Goodman, GR, et al., &amp; Saven, A (2003). Cladribine in the treatment of hairy-cell leukaemia. <i>Best practice &amp; research. Clinical haematology</i> 16(1) 101–116. DOI:<a href=&quot;https://doi.org/10.1016/s1521-6926(02)00089-0&quot;>10.1016/s1521-6926(02)00089-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12670469/&quot;>https://pubmed.ncbi.nlm.nih.gov/12670469</a></p></li><li><p>Poi, MJ, et al., &amp; Phelps, MA (2013). Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. <i>Clinical pharmacokinetics</i> 52(8) 705–712. DOI:<a href=&quot;https://doi.org/10.1007/s40262-013-0064-7&quot;>10.1007/s40262-013-0064-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23588536/&quot;>https://pubmed.ncbi.nlm.nih.gov/23588536</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX08;
